Some U.S. Employers Plan to End GLP-1 Obesity Drug Coverage in 2027, Even as Prices Fall
A Reuters report says roughly 10% of U.S. employers that currently cover GLP-1 medicines for weight loss intend to stop covering them in 2027. The move comes as enrollment in obesity-treating drugs continues to grow.
The decision is aimed at recouping cost pressures despite recent price cuts on Novo Nordisk's and Eli Lilly's GLP-1 products, Zepbound and Foundayo, which were expected to deliver savings for payers.
If coverage is reduced, the shift could curb demand for these high-cost therapies and affect revenue forecasts for the manufacturers, while patients may need to seek alternative funding sources.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more”
read at STAT ↗
comments(0)
5-min edit window · permanent after that